These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1080 related articles for article (PubMed ID: 34355795)

  • 21. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.
    Makdasi E; Zvi A; Alcalay R; Noy-Porat T; Peretz E; Mechaly A; Levy Y; Epstein E; Chitlaru T; Tennenhouse A; Aftalion M; Gur D; Paran N; Tamir H; Zimhony O; Weiss S; Mandelboim M; Mendelson E; Zuckerman N; Nemet I; Kliker L; Yitzhaki S; Shapira SC; Israely T; Fleishman SJ; Mazor O; Rosenfeld R
    Cell Rep; 2021 Sep; 36(10):109679. PubMed ID: 34464610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.
    Jennewein MF; MacCamy AJ; Akins NR; Feng J; Homad LJ; Hurlburt NK; Seydoux E; Wan YH; Stuart AB; Edara VV; Floyd K; Vanderheiden A; Mascola JR; Doria-Rose N; Wang L; Yang ES; Chu HY; Torres JL; Ozorowski G; Ward AB; Whaley RE; Cohen KW; Pancera M; McElrath MJ; Englund JA; Finzi A; Suthar MS; McGuire AT; Stamatatos L
    Cell Rep; 2021 Jul; 36(2):109353. PubMed ID: 34237283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
    Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
    J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
    Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
    mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics.
    Zhao S; Zhang H; Yang X; Zhang H; Chen Y; Zhan Y; Zhang X; Jiang R; Liu M; Liu L; Chen L; Tang W; Peng C; Gao X; Zhang Z; Shi Z; Gong R
    Nat Commun; 2021 Aug; 12(1):4887. PubMed ID: 34373446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishment of Neutralizing Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 by the Screening with Exosomes Expressing the Viral Spike Protein.
    Okada C; Ikeda-Ishizaka E; Ono C; Matsuura Y; Sonoda H
    Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):173-180. PubMed ID: 36027043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron.
    Casasnovas JM; Margolles Y; Noriega MA; Guzmán M; Arranz R; Melero R; Casanova M; Corbera JA; Jiménez-de-Oya N; Gastaminza P; Garaigorta U; Saiz JC; Martín-Acebes MÁ; Fernández LÁ
    Front Immunol; 2022; 13():863831. PubMed ID: 35547740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern.
    Morgan MS; Yan K; Le TT; Johnston RA; Amarilla AA; Muller DA; McMillan CLD; Modhiran N; Watterson D; Potter JR; Sng JDJ; Lor M; Paramitha D; Isaacs A; Khromykh AA; Hall RA; Suhrbier A; Rawle DJ; Hobson-Peters J
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel Conserved Linear Neutralizing Epitope on the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.
    Hua RH; Zhang SJ; Niu B; Ge JY; Lan T; Bu ZG
    Microbiol Spectr; 2023 Aug; 11(4):e0119023. PubMed ID: 37306579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
    Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
    Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
    Planchais C; Fernández I; Bruel T; de Melo GD; Prot M; Beretta M; Guardado-Calvo P; Dufloo J; Molinos-Albert LM; Backovic M; Chiaravalli J; Giraud E; Vesin B; Conquet L; Grzelak L; Planas D; Staropoli I; Guivel-Benhassine F; Hieu T; Boullé M; Cervantes-Gonzalez M; Ungeheuer MN; Charneau P; van der Werf S; Agou F; ; ; Dimitrov JD; Simon-Lorière E; Bourhy H; Montagutelli X; Rey FA; Schwartz O; Mouquet H
    J Exp Med; 2022 Jul; 219(7):. PubMed ID: 35704748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection.
    Beaudoin-Bussières G; Chen Y; Ullah I; Prévost J; Tolbert WD; Symmes K; Ding S; Benlarbi M; Gong SY; Tauzin A; Gasser R; Chatterjee D; Vézina D; Goyette G; Richard J; Zhou F; Stamatatos L; McGuire AT; Charest H; Roger M; Pozharski E; Kumar P; Mothes W; Uchil PD; Pazgier M; Finzi A
    Cell Rep; 2022 Feb; 38(7):110368. PubMed ID: 35123652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of SARS-CoV-2 pseudovirus invasion by ACE2 protecting and Spike neutralizing peptides: An alternative approach to COVID19 prevention and therapy.
    Chen J; Li S; Lei Z; Tang Q; Mo L; Zhao X; Xie F; Zi D; Tan J
    Int J Biol Sci; 2021; 17(11):2957-2969. PubMed ID: 34345219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.
    Tian X; Li C; Huang A; Xia S; Lu S; Shi Z; Lu L; Jiang S; Yang Z; Wu Y; Ying T
    Emerg Microbes Infect; 2020; 9(1):382-385. PubMed ID: 32065055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.
    Wan J; Xing S; Ding L; Wang Y; Gu C; Wu Y; Rong B; Li C; Wang S; Chen K; He C; Zhu D; Yuan S; Qiu C; Zhao C; Nie L; Gao Z; Jiao J; Zhang X; Wang X; Ying T; Wang H; Xie Y; Lu Y; Xu J; Lan F
    Cell Rep; 2020 Jul; 32(3):107918. PubMed ID: 32668215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies: a review].
    Chen Y; Lin J; Zheng P; Cao M; Jin T
    Sheng Wu Gong Cheng Xue Bao; 2022 Sep; 38(9):3173-3193. PubMed ID: 36151792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants.
    Wu WL; Chiang CY; Lai SC; Yu CY; Huang YL; Liao HC; Liao CL; Chen HW; Liu SJ
    JCI Insight; 2022 Apr; 7(8):. PubMed ID: 35290246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
    Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening.
    Schardt JS; Pornnoppadol G; Desai AA; Park KS; Zupancic JM; Makowski EK; Smith MD; Chen H; Garcia de Mattos Barbosa M; Cascalho M; Lanigan TM; Moon JJ; Tessier PM
    Sci Rep; 2021 Oct; 11(1):20738. PubMed ID: 34671080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy.
    Chiang CY; Chen MY; Hsu CW; Liu CY; Tsai YW; Liao HC; Yan JY; Chuang ZS; Wang HI; Pan CH; Yu CY; Yu GY; Liao CL; Liu SJ; Chen HW
    J Biomed Sci; 2022 Jun; 29(1):37. PubMed ID: 35681239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.